ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

DCT Board Approves Drug Development Recompetition

November 30, 1990

Black Women More Likely To Delay Diagnosis, Treatment

July 29, 2005

Heckler Announces NCI Team Headed By Gallo Has Found Cause Of AIDS

April 27, 1984

In Their Own Words: A 64-page Internal Report with over 1,500 Faculty Comments on MD Anderson Morale

March 29, 2013

Interview with FDA’s Richard Pazdur

October 30, 2009